FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileEmyria Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
EMD.AX
Emyria Limited Stock AnalysisComprehensive stock analysis for Emyria Limited (EMD.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisEMD.AX
EMD.AX
Emyria Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
EMD.AX
  1. Home
  2. Stocks
  3. Emyria Limited

Emyria Limited

🇦🇺EMD.AX•ASX

Emyria Limited

🇦🇺EMD.AX•ASX

Your view on EMD.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Emyria Limited

Industry
Medical - Healthcare Information Services
Sector
Healthcare
CEO
Gregory Hutchinson
Headquarters
D2, 661 Newcastle Street, Leederville, WA, AU
Industry
Medical - Healthcare Information Services
Sector
Healthcare
CEO
Gregory Hutchinson
Headquarters
D2, 661 Newcastle Street, Leederville, WA, AU
Description

Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs.

Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Emyria Limited. Starting points for Emyria Limited: EPS -AUD 0.0076, beta 0.03 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Emyria Limited. Emyria Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Emyria Limited. Trailing twelve-month EPS for Emyria Limited stands at -AUD 0.0076. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.01−AUD 0.01
Lowest estimate−AUD 0.01−AUD 0.01
Highest estimate−AUD 0.01−AUD 0.01
Number of analysts11
A year ago−AUD 0.011—
Growth vs a year ago——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 9.70MAUD 19.40M
Lowest estimateAUD 9.70MAUD 19.40M
Highest estimateAUD 9.70MAUD 19.40M
Number of analysts11
A year agoAUD 3.88M—
Growth vs a year ago+150.0%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Emyria Limited. Emyria Limited has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold EMD.AX20 companies
Compare EMD.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ADO.AXAnteoTech LimitedBasic MaterialsChemicals - Specialty—
AGN.AXArgenica Therapeutics LtdHealthcareBiotechnology—
BDX.AXBCAL Diagnostics LimitedHealthcareMedical - Diagnostics & Research—
DOC.AXDoctor Care Anywhere Group PLCHealthcareMedical - Healthcare Information Services—
EYE.AXNova Eye Medical LimitedHealthcareMedical - Devices—
IIQ.AXINOVIQ LtdHealthcareMedical - Diagnostics & Research—
LGP.AXLittle Green Pharma LtdHealthcareDrug Manufacturers - Specialty & Generic—
MAP.AXMicroba Life Sciences LimitedHealthcareMedical - Diagnostics & Research—
More Medical - Healthcare Information Services companies
TickerTypeCompanySectorExchangeMkt cap
EKGGFCardioComm Solutions, Inc.HealthcareOTC$1.4M
EMYSFEasy Technologies Inc.HealthcareOTC$142,220
ENL.AXEnlitic, Inc.HealthcareASX—
EVHEvolent Health, Inc.HealthcareNYSE$442.1M
EWLLeWellness Healthcare CorporationHealthcareOTC$185,077
FRLIFrélii, Inc.HealthcareOTC$5,347
GDRXGoodRx Holdings, Inc.HealthcareNASDAQ$1.1B
HCATHealth Catalyst, Inc.HealthcareNASDAQ$98.2M
HCTIHealthcare Triangle, Inc.HealthcareNASDAQ$2.4M
HDVYHealth Discovery CorporationHealthcareOTC$41,171
HIQ.AXHITIQ LimitedHealthcareASX—
HNGEHinge Health, Inc.HealthcareNYSE$9.3B
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Emyria Limited. Coverage tracks Emyria Limited within Medical - Healthcare Information Services (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Emyria Limited.

EMD.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1